Cargando…

Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada

IMPORTANCE: The risk of myocarditis or pericarditis after COVID-19 messenger RNA vaccines varies by age and sex, and there is some evidence to suggest increasing risk with shorter intervals between dose 1 and 2 (ie, interdose interval). OBJECTIVE: To estimate the incidence of reported myocarditis or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buchan, Sarah A., Alley, Sarah, Seo, Chi Yon, Johnson, Caitlin, Kwong, Jeffrey C., Nasreen, Sharifa, Thampi, Nisha, Lu, Diane, Harris, Tara M., Calzavara, Andrew, Wilson, Sarah E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972235/ https://www.ncbi.nlm.nih.gov/pubmed/36848096 http://dx.doi.org/10.1001/jamapediatrics.2022.6166

Ejemplares similares

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada
por: Buchan, Sarah A., et al.
Publicado: (2022)

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
por: Nasreen, Sharifa, et al.
Publicado: (2022)

Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments
por: Sundaram, Maria, et al.
Publicado: (2021)

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
por: Chung, Hannah, et al.
Publicado: (2021)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
por: Katoto, Patrick D. M. C., et al.
Publicado: (2023)

Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study
por: Chung, Hannah, et al.
Publicado: (2022)

Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study
por: Nasreen, Sharifa, et al.
Publicado: (2021)

Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines
por: Abraham, Natalia, et al.
Publicado: (2022)

INCESSANT PERICARDITIS AND CARDIAC TAMPONADE FOLLOWING THE BNT162B2 MRNA COVID-19 VACCINE
por: Rodden, Diane, et al.
Publicado: (2022)

Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
por: Uesako, Hayata, et al.
Publicado: (2022)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Myocarditis after BNT162b2 vaccination in a healthy male
por: Watkins, Kevin, et al.
Publicado: (2021)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada
por: Leigh Hobbs, J., et al.
Publicado: (2023)

Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study
por: Martins, Diana, et al.
Publicado: (2020)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
por: Bautista García, Javier, et al.
Publicado: (2021)

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19
por: Cueva-Recalde, Juan F., et al.
Publicado: (2023)

COVID-19, Myocarditis and Pericarditis
por: Fairweather, DeLisa, et al.
Publicado: (2023)

Effusive–constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): a case report
por: Viani, Giacomo Maria, et al.
Publicado: (2022)

BNT162B2 MRNA BOOSTER VACCINE-RELATED PERICARDITIS: A CASE COMPLICATED BY PERICARDIAL AND PLEURAL EFFUSIONS
por: WHITE, ANESHA, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine
por: Fosch, Xavier, et al.
Publicado: (2022)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Giant cell myocarditis after first dose of BNT162b2 – a case report
por: Hirsch, Valentin G., et al.
Publicado: (2022)

Myocarditis and Pericarditis in Patients with COVID-19
por: Shah, Jassim Zaheen, et al.
Publicado: (2020)

Tozinameran: Myocarditis and pericarditis: case report
Publicado: (2022)

Variation in Care of Community and Nursing Home Residents Who Died of COVID-19 in Ontario, Canada
por: Brown, Kevin A., et al.
Publicado: (2021)

1759. Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002–2016
por: Buchan, Sarah, et al.
Publicado: (2019)

Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study
por: Grewal, Ramandip, et al.
Publicado: (2022)

Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
por: Kim, Hyeonhui, et al.
Publicado: (2023)

1211. Incidence of All-Cause Community-Acquired Pneumonia in Ontario and British Columbia, Canada, 2002-2018; a Canadian Immunization Research Network (CIRN) study
por: Nasreen, Sharifa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ma2ulc1kdru6h0bm6ikj99mggn